ABSTRACT-The effects of D-Ala2-D-Leu5-enkephalin (DADL, a o-opioid agonist), microinjected directly into the hypothalamic supraoptic (SON) and paraventricular (PVN) nuclei, on urine outflow rate, urinary osmotic pressure, blood pressure, heart rate, respiratory rate and rectal temperature were investigated in water-loaded and ethanol-anesthetized rats. The microinjection of DADL into both the nuclei decreased urine outflow rate in a dose-dependent manner with an increase in urinary osmotic pressure, but did not change the other recorded parameters. The DADL-induced antidiuretic effect in the SON was inhibited by naloxone, but not by atropine, phenoxybenzamine, timolol nor a vasopressin antagonist, d(CH2)5-D Tyr(Et)VAVP. The effect in the PVN was inhibited by naloxone, atropine, timolol and d(CH2)5-D Tyr(Et)VAVP, but not by phenoxybenzamine. These results suggest that DADL causes antidiuretic effects mediated through opioid receptors in both the SON and PVN, and the underlying mechanisms are different between them. Involvement of o-opioid receptors in the DADL-induced antidiureses was discussed.
The hypothalamic supraoptic (SON) and paraventri cular (PVN) nuclei include cell bodies of vasopressin-con taining neurons and projecting neurons to the neuro hypophysis, the brain stem, the spinal cord and others. Vasopressin release is regulated by various transmitters such as norepinephrine (1) (2) (3) , acetylcholine (1, 4) , hista mine (1, 3) and angiotensin II (1, 3) in the nuclei, and thus changes the urine outflow rate.
In addition, the SON and PVN contain opioid pep tides, derived from proopiomelanocortin, and proen kephalin A and B (5 9), some of which coexist with vasopressin (8, 10, 11) . Immunohistochemical studies show fibers and terminals of opioid neurons in the nuclei (5 7, 11-13) . These opioid peptides appear to play a role in the vasopressin release and the regulation of urine outflow rate. It was demonstrated that intra cerebroventricular (i.c.v.) injection of morphine, a p agonist, increases vasopressin release and causes anti diureses (14, 15) . On the other hand, i.c.v. injection of dynorphin or bremazocine, K-agonists, produces the oppo site effects (16, 17) . Also, we have reported the antidiuret ic effect induced by microinjection of morphine or fen tanyl into the nuclei (18, 19) . However, the roles of o agonists in the regulation are not well known. Therefore, the present experiments are designed to study the effects of D-Ala2-D-Leu5-enkephalin (DADL), a relatively selec tive 5-agonist (20) , on urine outflow rate in the nuclei.
MATERIALS AND METHODS

Animals
Adult male Wistar rats (300-370g) were used. The animals were housed with a 12-hr light/dark cycle and given food and tap water ad libitum. They were removed from food for approximately 19 hr before the experi ments were started.
Experimental protocol
The rats were orally loaded with water (5 ml/ 100 g body weight); and 45 min later, they were given the same volume of 12% ethanol for anesthesia. The animals were inserted with cannulae into the trachea, the jugular vein and the urinary bladder. Locke solution (3010 ethanol) was continuously infused through the jugular vein cannula at 0.1 ml/min. The ethanol-anesthetized and ethanol-in fused condition kept the urine outflow rate measurable and constant for 5 6 hr. The rats were implanted with another cannula, attached to a transducer (MPU-0.5-290 0-III; Nihon Kohden Kogyo, Tokyo), into the jugular artery for measurement of blood pressure; and thermister probes were inserted into the tracheal cannula and rectum (SR-115 and MGA 111-219, Nihon Kohden Kogyo, Co.) for measurement of respiratory rate and rectal tempera ture, respectively. Heart rate was monitored by cardio graphy (FD-14; Fukuda, Tokyo). Then the animal was placed in a stereotaxic instrument (Takahashi Co., Tokyo), and a stainless steel cannula (diameter: 200,um) was inserted into the SON or PVN according to the atlas of Konig and Klippel (21) . After 30 60 min, the urine outflow from the bladder cannula reached a constant rate of 0.04-0.20 ml/min. All drugs were dissolved in saline, which was used as the vehicle. Solutions of vasopressin (0.1 ml) and d(CH2)5-D-Tyr(Et)VAVP (0.2 ml) were inject ed intravenously. The other drug solution (1 pl), followed by an artificial cerebrospinal fluid (2 pl) (22) for washing out the dead space of the cannula, was microinjected into the nucleus for 10 min through a microsyringe which was connected to the stainless steel cannula in the nucleus. The number of urine drops was counted every 10 min by a photoelectric counter (DCT 102; Unique Medical, Inc., Tokyo) and was expressed as a percentage of the control (the number of urine drops for 10 min before the micro injection). Urinary osmotic pressure was measured by the freezing point depression method (The Fiske Osmometer, Model G-62; Fiske Associates, Inc., Uxbridge, MA, USA).
Injection sites in the SON and PVN were verified from coronal 15-,um sections, which were cut using a freezing microtome (Tissue-Tek II; Miles Inc., Erkhart, IN, USA) and were stained with hematoxylin-eosin.
Statistical analyses
All values are presented as the mean ±S.E. Significance of differences was determined by Student's t-test at P < 0.05. 
RESULTS
Effects of DADL microinjected into the SON and PVN Urine outflow rate from the bladder cannula was con stant, 0.04-0.20 ml/min, for 5-6 hr from 30-60 min after all was set. The microinjection of vehicle (saline) into the SON and PVN did not change the urine outflow rate nor the other recorded indices.
As shown in Fig. 1, 4 nmol of DADL, microinjected into the SON, began to decrease the urine outflow rate within 20 min, reached a maximum response at 30-40 min and returned it to the control level by 80 min after the microinjection.
The antidiuretic effects were dose-de pendent from a dose of 0.5 nmol to 10 nmol (Fig. 2) . The microinjection of DADL into the PVN also elicited antidiuretic effects, which showed similar potency to those in the SON (Fig. 2) . Urinary osmotic pressure was measured to examine the intervention of vasopressin release in the antidiuretic effects. The microinjection of 10 nmol DADL significant ly increased the osmotic pressure to 202±26010 of the con trol level at 30 min in the SON (n = 4) and 228 _±:17 010 of the control level at 40 min in the PVN (n=6). At these times, the urine outflow rates showed the maximum decrease, which were 6±401o and 7±3% of the control level in the SON and PVN, respectively. When the urine outflow rate recovered to the control level at 80-120 min after the injection, urinary osmotic pressure also returned to the control level. The control urinary osmotic pressure Neither blood pressure, heart rate, respiratory rate nor rectal temperature were changed during the antidiuretic effects induced by 10 nmol DADL in the nuclei. (Fig. 3a) . The vasopressin-induced antidiureses were reproducible in the same rat. Figure 3 (b and c) shows the effects of d(CH2)5-D-Tyr(Et)VAVP on the DADL-in duced effects in the SON and PVN, respectively. The an tagonist partially inhibited the antidiuretic effect in the PVN, but did not do so in the SON.
In Figs. 4 and 5, the effects of an opioid antagonist, naloxone (NAL, 600 nmol); a muscarinic antagonist, atropine (ATR, 300 nmol); an a-adrenergic antagonist, phenoxybenzamine (PHE, 80 nmol); and a (3-adrenergic antagonist, timolol (TIM, 100 nmol), microinjected into the nuclei, on the DADL-induced antidiureses are shown. NAL at 300 nmol partially inhibited the DADL-induced antidiureses in both the nuclei (SON: 13--L7.0% vs. 41±8.4% at 30 min, 22±7.4% vs. 48±9.9% at 40 min, n=4; PVN: 6±2.8010 vs. 53± 14010 at 30 min, 10±3.4% vs. 53± 11 % at 40 min, n=4; P <0.05). A previous study showed that this dose of NAL produced complete inhibi tion of the antidiureses induced by 10 nmol morphine, a p-agonist (18) . The higher dose, 600 nmol, of NAL in hibited the DADL-induced antidiureses more strongly than 300 nmol of NAL. However, the weak and sig nificant antidiuretic effect remained (Figs. 4a and 5a) . Microinjection of 300 or 600 nmol NAL alone into the nuclei decreased the urine outflow rate. The other an tagonists did not influence the DADL-induced anti diureses in the SON (Fig. 4, b d) . On the other hand, in the PVN, ATR and TIM inhibited the effect, but PHE did not (Fig. 5, b d) . All of these inhibitory effects were par tial. In the PVN, ATR at the smaller dose, 2 nmol, showed a tendency to inhibit the effects, but not signifi cantly (n=7). The doses of the cholinergic and adre nergic antagonists were sufficient to inhibit the effects of each agonist in the same method (24-26). 
DISCUSSION
This study showed that the microinjection of DADL into the SON and PVN elicited the antidiuretic effects that were antagonized by NAL, suggesting opioid-receptor mediated effects. The opioid receptors seem to be 6-sub types, at least in part, for the following reasons: 1) A higher dose of NAL was required to inhibit the DADL-in duced antidiuretic effects than the morphine-induced anti diuretic effects. In receptor binding studies, the affinity of NAL for 5-receptors is 15-times less than that for p-recep tors (27) ; 2) The effects of the adrenergic and cholinergic antagonists on the DADL-induced effects were different from those on the morphine-induced one (18, mentioned below), and, at least, the DADL-binding opioid receptors are not p-subtypes; 3) DADL is thought to be relatively selective for 5-receptors (20) , and 4) autoradiography shows the presence of 6-receptors in the nuclei (28) .
Microinjection of NAL alone into the nuclei produced the antidiureses. Because the doses used were relatively high, the antidiureses may be an agonistic effect. We have already investigated the effects of the drug solution osmot ic pressure on urine outflow rate using NaCl. The ED50 values for NaCl-induced antidiureses were > 3.2 pmol in the SON and 1.1 ppmol in the PVN (25, 26) . This suggests that the osmotic pressure of the drug solution influences urine outflow rate, but it is weak.
ATR and TIM inhibited the DADL-induced effect in the PVN, but not in the SON. From these results, it is sug gested that the antidiuretic effect of DADL in the PVN in volves adrenergic and cholinergic mechanisms, but that in the SON does not involve them. The DADL-binding opioid receptors may have different properties from p receptors in the nuclei. That is, ,u-receptors induced the antidiuretic effects mediated only through a cholinergic mechanism in both the nuclei, because the morphine induced effects were inhibited by ATR, but not by PHE nor TIM (18) .
Microinjection of DADL into the PVN is suggested to promote vasopressin release, because d(CH2)5-D Tyr(Et)VAVP inhibited the DADL-induced antidiuretic effect. However, this inhibitory effect was partial, although the dose of the antagonist used in this study was sufficient to block the antidiuretic effect induced by 4 mU vasopressin, which was almost the same as the DADL (4 nmol)-induced one. In addition, the increase in urinary osmotic pressure induced by DADL was not as much as that by vasopressin. DADL increased the urinary osmotic pressure to approximately 2 times the control level in the PVN. Our previous result shows that the increase in os motic pressure by vasopressin (4 mU, i.v.), which elicited antidiureses with a similar potency to DADL, was 3.5 times the control level (29) . Therefore, it is possible that other mechanisms may intervene in the effect. On the other hand, because in the SON, the DADL-induced effects before and after the pretreatment with d(CH2)5-D Tyr(Et)VAVP were not different significantly, the anti diureses did not seem to be mediated through an in crease in vasopressin release. This finding is consistent with the electrophysiological result that DADL does not influence the firing rate of vasopressin-containing neu rons in the SON (30) . DADL did not change the blood pressure nor heart rate when it induced the antidiuretic effects. Electrophysiological studies show that there is a neuronal connection between the hypothalamic nuclei and the kidney (31) (32) (33) . In addition, some drugs in the hypothalamus produced antidiuretic effects without in creasing vasopressin release (32, 34, 35 
